This morning we received news that the B3TXF (Bollgard 3, Thryvon, Xtendflex) trait package received its final key export approval, meaning that Thryvon will be fully commercialized in the U.S. this year and the “stewarded” status on this technology has been lifted.

I have attached the Bayer news release to this blog post. If you have any questions about this new technology, contact me.

Posted in: